Invasive Meningococcal Disease: What We Should Know, Before It Comes Back.
Invasive meningococcal disease
sepsis
sequelae
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
04
12
2018
accepted:
05
02
2019
entrez:
6
4
2019
pubmed:
6
4
2019
medline:
6
4
2019
Statut:
epublish
Résumé
Invasive meningococcal disease (IMD), sepsis and/or meningitis continues to be a public health problem, with mortality rates ranging from 5% to 16%. The aim of our study was to further knowledge about IMD with a large series of cases occurring over a long period of time, in a cohort with a high percentage of adult patients. Observational cohort study of patients with IMD between 1977 hand 2013 at our hospital, comparing patients with only sepsis and those with meningitis and several degrees of sepsis. The impact of dexamethasone and prophylactic phenytoin was determined, and an analysis of cutaneous and neurological sequelae was performed. A total of 527 episodes of IMD were recorded, comprising 57 cases of sepsis (11%) and 470 of meningitis with or without sepsis (89%). The number of episodes of IMD decreased from 352 of 527 (67%) in the first to 20 of 527 (4%) in the last quarter ( The frequency of IMD has decreased sharply since 1977. Patients with sepsis only have the highest mortality and complication rates, dexamethasone use is safe and can prevent some arthritis episodes, and prophylactic phenytoin might be useful in a selected population. A rapid response and antibiotic therapy may help improve the prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Invasive meningococcal disease (IMD), sepsis and/or meningitis continues to be a public health problem, with mortality rates ranging from 5% to 16%. The aim of our study was to further knowledge about IMD with a large series of cases occurring over a long period of time, in a cohort with a high percentage of adult patients.
METHODS
METHODS
Observational cohort study of patients with IMD between 1977 hand 2013 at our hospital, comparing patients with only sepsis and those with meningitis and several degrees of sepsis. The impact of dexamethasone and prophylactic phenytoin was determined, and an analysis of cutaneous and neurological sequelae was performed.
RESULTS
RESULTS
A total of 527 episodes of IMD were recorded, comprising 57 cases of sepsis (11%) and 470 of meningitis with or without sepsis (89%). The number of episodes of IMD decreased from 352 of 527 (67%) in the first to 20 of 527 (4%) in the last quarter (
CONCLUSIONS
CONCLUSIONS
The frequency of IMD has decreased sharply since 1977. Patients with sepsis only have the highest mortality and complication rates, dexamethasone use is safe and can prevent some arthritis episodes, and prophylactic phenytoin might be useful in a selected population. A rapid response and antibiotic therapy may help improve the prognosis.
Identifiants
pubmed: 30949522
doi: 10.1093/ofid/ofz059
pii: ofz059
pmc: PMC6440684
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz059Références
Pediatr Infect Dis J. 1999 Jul;18(7):633-4
pubmed: 10440442
Arch Intern Med. 1999 Oct 25;159(19):2329-40
pubmed: 10547173
N Engl J Med. 2001 May 3;344(18):1378-88
pubmed: 11333996
Euro Surveill. 2004 Jul;9(7):11-5
pubmed: 15318008
An Pediatr (Barc). 2005 Apr;62(4):297-303
pubmed: 15826557
Lancet. 2007 Jun 30;369(9580):2196-2210
pubmed: 17604802
Curr Opin Pediatr. 2009 Aug;21(4):437-43
pubmed: 19421058
Rev Esp Salud Publica. 2009 Sep-Oct;83(5):725-35
pubmed: 20111820
Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S45-53
pubmed: 20144016
N Engl J Med. 2010 Apr 22;362(16):1511-20
pubmed: 20410516
J Infect Public Health. 2010 Dec;3(4):143-51
pubmed: 21126718
Vaccine. 2011 Aug 5;29(34):5765-70
pubmed: 21664402
Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2661-6
pubmed: 22476361
Vaccine. 2012 May 30;30 Suppl 2:B57-62
pubmed: 22607900
Neurology. 2012 Oct 9;79(15):1563-9
pubmed: 22972648
J Infect. 2013 Feb;66(2):147-54
pubmed: 23168216
Popul Health Metr. 2013 Sep 10;11(1):17
pubmed: 24016339
BMJ. 2014 Apr 02;348:g2415
pubmed: 24696308
Acta Med Port. 2014 May-Jun;27(3):291-4
pubmed: 25017339
Clin Infect Dis. 2014 Nov 1;59(9):1216-21
pubmed: 25069869
Lancet Infect Dis. 2014 Sep;14(9):805-12
pubmed: 25104306
Clin Infect Dis. 2015 Feb 15;60(4):578-85
pubmed: 25389259
Expert Rev Vaccines. 2017 Apr;16(4):313-328
pubmed: 27820969
Clin Infect Dis. 2017 Sep 1;65(5):756-763
pubmed: 28505234
Lancet. 1985 Oct 12;2(8459):829-30
pubmed: 2864546
J Infect. 2017 Nov;75(5):420-425
pubmed: 28847701
Arch Intern Med. 1986 Dec;146(12):2380-2
pubmed: 3778073
JAMA. 1984 Feb 10;251(6):788-90
pubmed: 6363729